Status:
COMPLETED
A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients
Lead Sponsor:
AstraZeneca
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
Lung cancer is one of the most deadly types of cancer and the leading cause of death in cancer in Sweden. Five year survival is 10% in men and 15% in women. Approximately 3300 individuals in Sweden ar...
Eligibility Criteria
Inclusion
- Diagnosis code C34 (ICD-10).
- Inoperable lung cancer.
- Diagnosis of lung cancer made between 2010-05-31 and 2009-06-01.
Exclusion
- Diagnosis code C34.9b.
- Diagnosis code C34.9h.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT01139619
Start Date
October 1 2010
End Date
January 1 2013
Last Update
February 25 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Gävle, Sweden
2
Research Site
Linköping, Sweden
3
Research Site
Luleå, Sweden